NasdaqGS - Nasdaq Real Time Price USD

Immunocore Holdings plc (IMCR)

58.46

+0.46

(+0.79%)

At close: April 26 at 4:00 PM EDT

58.46

0.00

(0.00%)

After hours: April 26 at 4:20 PM EDT

Immunocore announces upcoming presentation and posters at ASCO 2024

Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to ra

GlobeNewswire 2 days ago

IMCR
+0.79%
Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor confere

GlobeNewswire 22 days ago

IMCR
+0.79%
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

Since Bill Gates left his position with Microsoft (NASDAQ:MSFT) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest. Gates was one of the loudest voices during the Covid-19 pandemic for providing therapeutics to poor countries and elsewhere. His Bill and Melinda Gates Foundation used its clout to influence response to the disease by governments around the world. The Foundation also gave more than $1 billion to the World Health Organiza

InvestorPlace last month

VIR

IMCR
+0.79%
BNTX
Immunocore presented two posters at CROI 2024

Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases,

GlobeNewswire last month

IMCR
+0.79%
Immunocore Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Immunocore Holdings ( NASDAQ:IMCR ) Full Year 2023 Results Key Financial Results Revenue: US$249.4m (up 44% from FY...

Simply Wall St. last month

IMCR
+0.79%
Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript February 28, 2024 Immunocore Holdings plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the Immunocore Fourth Quarter Financial Results Conference Call. At this time, all participants are […]

Insider Monkey last month

IMCR
+0.79%
Immunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...

Full Year and Q4 2023 Earnings Summary: KIMMTRAK Drives Revenue Surge as Clinical Pipeline Progresses

GuruFocus.com last month

IMCR
+0.79%
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) with nivol

GlobeNewswire last month

IMCR
+0.79%
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial IMC-F106C is Immunocore’s first-in-class bispecific TCR ImmTAC candidate targeting PRAME HLA-A02; nivolumab is manufactured by Bristol Myers Squibb The clinical trial collaboration relates to Immunocore’s PRISM-MEL-301 registrational Phase 3 clinical trial in

GlobeNewswire 2 months ago

IMCR
+0.79%
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it wi

GlobeNewswire 2 months ago

IMCR
+0.79%
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Zacks 2 months ago

ADMA

ROG.SW

IMCR
+0.79%
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.

Zacks 2 months ago

EXEL

EDIT

IMCR
+0.79%
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.

Zacks 2 months ago

ZTS

IMCR
+0.79%
5 Biotech Stocks to Consider for Your Portfolio in 2024

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

Zacks 2 months ago

^GSPC

IMCR
+0.79%
EDIT
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Zacks 2 months ago

IMVT

IMCR
+0.79%
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.

Zacks 2 months ago

IMCR
+0.79%
IMGN

PBYI
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.

Zacks 2 months ago

RGNX

IMCR
+0.79%
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.

Zacks 2 months ago

IMNM

IMCR
+0.79%
PBYI
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

Zacks 2 months ago

DCPH

IMCR
+0.79%
IMGN
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 2 months ago

IMCR
+0.79%
VTGN

Performance Overview

Return	IMCR	MSCI WORLD
YTD	-14.43%	+5.23%
1-Year	-1.88%	+19.98%
3-Year	+47.44%	+12.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immunocore Holdings plc (IMCR)

Immunocore announces upcoming presentation and posters at ASCO 2024

Immunocore to present at upcoming investor conferences

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

Immunocore presented two posters at CROI 2024

Immunocore Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript

Immunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

5 Biotech Stocks to Consider for Your Portfolio in 2024

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

Performance Overview